NRAS and cancer: The increasing use of ctDNA analysis at disease progression and lack of a standardized cutoff for NRAS or other oncogene amplification using FISH or NGS testing on tumor biopsy samples may contribute to the underrepresentation of gene amplification as an important bypass signaling resistance mechanism in cancers.